Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Assess Mechanism Of Action (Moa) Of Cp-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (Bid) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: Group 1: Approved q12w maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Arm Label: Group 2: Subject-tailored fixed-interval maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen
C: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Apremilast 30 mg plus placebo injection; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo injection | Arm Label: Etanercept 50 mg plus placebo tablet; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Placebo tablet | Arm Label: Oral placebo tablets plus SC placebo injections; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo injection | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg plus placebo injection | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg plus placebo tablet | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Etanercept 50 mg plus placebo tablet, Oral placebo tablets plus SC placebo injections | Intervention Type: DRUG; Name: Placebo injection; Assigned to Arm(s): Apremilast 30 mg plus placebo injection, Oral placebo tablets plus SC placebo injections

Answer: A